These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 27048227)
1. The lack of Lazarus effect with proteasome inhibition. Marks SD Pediatr Nephrol; 2016 Aug; 31(8):1217-9. PubMed ID: 27048227 [TBL] [Abstract][Full Text] [Related]
2. Bortezomib for refractory acute antibody-mediated rejection in kidney transplant recipients: A single-centre case series. De Sousa-Amorim E; Revuelta I; Diekmann F; Cofan F; Lozano M; Cid J; Palou E; Sole M; Campistol JM; Oppenheimer F Nephrology (Carlton); 2016 Aug; 21(8):700-4. PubMed ID: 26492594 [TBL] [Abstract][Full Text] [Related]
3. Bortezomib may stabilize pediatric renal transplant recipients with antibody-mediated rejection. Pearl MH; Nayak AB; Ettenger RB; Puliyanda D; Palma Diaz MF; Zhang Q; Reed EF; Tsai EW Pediatr Nephrol; 2016 Aug; 31(8):1341-8. PubMed ID: 27048228 [TBL] [Abstract][Full Text] [Related]
4. Successful treatment of severe acute antibody-mediated rejection of renal allografts with bortezomib--a report of two pediatric cases. Roberti I; Vyas S Pediatr Transplant; 2015 Dec; 19(8):E189-92. PubMed ID: 26455511 [TBL] [Abstract][Full Text] [Related]
5. Management of Plasma Cell-Rich Acute Rejection in Living-Related Kidney Transplant: Role of Proteasome Inhibitor. Abbas K; Mubarak M; Zafar MN; Musharraf W; Imam M; Aziz T; Rizvi AH Exp Clin Transplant; 2019 Feb; 17(1):42-46. PubMed ID: 29534661 [TBL] [Abstract][Full Text] [Related]
6. A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection. Eskandary F; Regele H; Baumann L; Bond G; Kozakowski N; Wahrmann M; Hidalgo LG; Haslacher H; Kaltenecker CC; Aretin MB; Oberbauer R; Posch M; Staudenherz A; Handisurya A; Reeve J; Halloran PF; Böhmig GA J Am Soc Nephrol; 2018 Feb; 29(2):591-605. PubMed ID: 29242250 [TBL] [Abstract][Full Text] [Related]
7. Protective immunity and use of bortezomib for antibody-mediated rejection in a pediatric kidney transplant recipient. Claes DJ; Yin H; Goebel J Pediatr Transplant; 2014 Jun; 18(4):E100-5. PubMed ID: 24725066 [TBL] [Abstract][Full Text] [Related]
8. Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection. Waiser J; Budde K; Schütz M; Liefeldt L; Rudolph B; Schönemann C; Neumayer HH; Lachmann N Nephrol Dial Transplant; 2012 Mar; 27(3):1246-51. PubMed ID: 21852274 [TBL] [Abstract][Full Text] [Related]
9. Bortezomib Eliminates Plasma Cells From a Renal Graft in Plasma Cell-Rich Acute Rejection. Tasaki M; Saito K; Nakagawa Y; Ikeda M; Imai N; Ito Y; Sudo M; Ikezumi Y; Yamada T; Hasegawa H; Kobayashi T; Miura K; Narita I; Takahashi K; Tomita Y Transplant Proc; 2019; 51(6):1732-1738. PubMed ID: 31301858 [TBL] [Abstract][Full Text] [Related]
10. The effect of race and ethnicity on kidney allograft outcome. Katznelson S; Gjertson DW; Cecka JM Clin Transpl; 1995; ():379-94. PubMed ID: 8794281 [TBL] [Abstract][Full Text] [Related]